Type-B monoamine oxidase inhibitors, such as rasagiline (Azilect) and selegiline (Deprenyl), treat Parkinson’s patients by ameliorating motor symptoms and improving motor fluctuations, and their evaluation in preclinical studies has indicated that they hold strong neuroprotective potential in Parkinson’s and other neurodegenerative diseases by reducing oxidative stress [51]. This evidence concerns the gene MAOB and Parkinson disease.